Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Dirix

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|February 28, 2018
Adjuvant aromatase inhibition: more options for patientsLuc Y Dirix
The Lancet. Oncology|October 3, 2014
Bevacizumab beyond progression in breast cancerLuc Y Dirix, Andrew R Reynolds
The Lancet. Oncology|March 2, 2012
Inflammatory HER2-positive breast cancerLuc Y Dirix, Peter B Vermeulen
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Neoadjuvant and adjuvant therapy for invasive bladder tumorsL Y Dirix, A T Van Oosterom
Seminars in Oncology|February 1, 1989
The role of ifosfamide in the treatment of sarcomasL Y Dirix, A T Van Oosterom
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2007
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitorsL Y Dirix, H Maes, C Sweldens
Lancet (London, England)|April 20, 2002
Gene-expression profiling to classify soft-tissue sarcomasLuc Y Dirix, Allan T van Oosterom
Current Opinion in Oncology|July 1, 1994
Diagnosis and treatment of soft tissue sarcomas in adultsL Y Dirix, A T Van Oosterom
Current Opinion in Oncology|July 23, 1999
Soft tissue sarcoma in adultsL Y Dirix, A T Van Oosterom
Current Opinion in Oncology|July 1, 1995
Diagnosis and treatment of soft tissue sarcomas in adultsL Y Dirix, A T Van Oosterom
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|February 28, 2018
Adjuvant aromatase inhibition: more options for patientsLuc Y Dirix
The Lancet. Oncology|October 3, 2014
Bevacizumab beyond progression in breast cancerLuc Y Dirix, Andrew R Reynolds
The Lancet. Oncology|March 2, 2012
Inflammatory HER2-positive breast cancerLuc Y Dirix, Peter B Vermeulen
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Neoadjuvant and adjuvant therapy for invasive bladder tumorsL Y Dirix, A T Van Oosterom
Seminars in Oncology|February 1, 1989
The role of ifosfamide in the treatment of sarcomasL Y Dirix, A T Van Oosterom
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2007
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitorsL Y Dirix, H Maes, C Sweldens
Lancet (London, England)|April 20, 2002
Gene-expression profiling to classify soft-tissue sarcomasLuc Y Dirix, Allan T van Oosterom
Current Opinion in Oncology|July 1, 1994
Diagnosis and treatment of soft tissue sarcomas in adultsL Y Dirix, A T Van Oosterom
Current Opinion in Oncology|July 23, 1999
Soft tissue sarcoma in adultsL Y Dirix, A T Van Oosterom
Current Opinion in Oncology|July 1, 1995
Diagnosis and treatment of soft tissue sarcomas in adultsL Y Dirix, A T Van Oosterom
Pageof 20